The estimated Net Worth of Richard B Slansky is at least 102 千$ dollars as of 6 July 2015. Richard Slansky owns over 150,000 units of OncoSec Medical Inc stock worth over 42,000$ and over the last 16 years Richard sold ONCS stock worth over 59,796$.
Richard has made over 17 trades of the OncoSec Medical Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Richard bought 150,000 units of ONCS stock worth 918,000$ on 6 July 2015.
The largest trade Richard's ever made was buying 150,000 units of OncoSec Medical Inc stock on 6 July 2015 worth over 918,000$. On average, Richard trades about 10,644 units every 56 days since 2009. As of 6 July 2015 Richard still owns at least 150,000 units of OncoSec Medical Inc stock.
You can see the complete history of Richard Slansky stock trades at the bottom of the page.
Richard's mailing address filed with the SEC is 9810 SUMMERS RIDGE ROAD, SUITE 110, SAN DIEGO, CA, 92121.
Over the last 12 years, insiders at OncoSec Medical Inc have traded over 1,474,366$ worth of OncoSec Medical Inc stock and bought 9,275,650 units worth 39,853,210$ . The most active insiders traders include Grand Pharmaceutical & Heal...、Holdings, Inc. Alpha、Robert Ward. On average, OncoSec Medical Inc executives and independent directors trade stock every 62 days with the average trade being worth of 51,563$. The most recent stock trade was executed by Robert J Del Aversano on 9 February 2023, trading 40 units of ONCS stock currently worth 55$.
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
OncoSec Medical Inc executives and other stock owners filed with the SEC include: